Beryl Drugs Limited

BSE: 524606
Beryl Drugs Limited - pharma in Indore, Madhya Pradesh, India. FY 2026 financials and compliance.
CIN L02423MP1993PLC007840 Incorporated 24 August 1993 ROC Gwalior HQ Indore, Madhya Pradesh, India
Active Listed - BSE: 524606 Public Limited Company pharma
Data last updated
Revenue · FY 2026
₹18.82 Cr
▼ 11% YoY
Computed EBITDA · FY 2026
₹2.43 Cr
▼ 8.16% YoY
Net profit · FY 2026
₹42.48 Lakh
▼ 26.62% YoY
Authorised capital
₹10 Cr
Registered with MCA
Paid-up capital
₹5.07 Cr
Issued & subscribed
Open charges
₹2.85 Cr
Satisfied ₹9.99 Cr
Company age
33 yrs
Est. 1993
Employees · EPFO
22
Latest available

About Beryl Drugs Limited

Data last updated: 13 July 2026

Beryl Drugs Limited is a public limited company based in Indore, Madhya Pradesh, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 24 August 1993, the company has been in operation for over 33 years.

Registered with ROC Gwalior under CIN U02423MP1993PLC007840. Listed on BSE: 524606.

Capital: an authorised share capital of ₹10 Cr and a paid-up capital of ₹5.07 Cr. It is led by directors including Sudhir Sethi and Abhinav Naik.

Last AGM: 30 September 2025. Financial statements filed for year ended 31 March 2025. Office: 29 Neer Nagar Mayank Water Park Road Bicholi, Indore, Madhya Pradesh, India – 452016.

As per BSE-filed standalone financials for FY 2026, the company reported a revenue of ₹18.82 Cr, a decline of 11% compared to the previous year. The net worth stands at ₹9.89 Cr (up 4.04% YoY). Total assets are valued at ₹14.96 Cr (down 6.24% YoY).

The company has a workforce of approximately 22 employees as per the latest available data.

The company is associated with 1 brand - Beryl Drugs. As per MCA filings, the company has open charges of ₹2.85 Cr and satisfied charges of ₹9.99 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website beryldrugs.com.

Company Details of Beryl Drugs Limited
CIN L02423MP1993PLC007840
Registration Number 007840
Incorporation Date 24 August 1993
ROC Gwalior
Listing Status Listed (BSE: 524606)
Company Status Active
Date of Last AGM 30 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Sanjay Sethi Managing Director Sudhir Sethi Director Abhinav Naik Director
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    Locked
  • Social Media
  • Registered Address
    29 Neer Nagar Mayank Water Park Road Bicholi, Indore, Madhya Pradesh, India – 452016
  • Industry
    Pharma, Drug Formulation & Development
Company report
Beryl Drugs Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Beryl Drugs Limited report

Financials, compliance, directors, charges, ownership and filings for Beryl Drugs Limited in one report.

10-year financials Directors & ownership Charges & compliance

CIN History of Beryl Drugs Limited

Beryl Drugs Limited has one previous CIN (Corporate Identification Number): U02423MP1993PLC007840. The current CIN is L02423MP1993PLC007840, which is the unique identifier assigned by the Registrar of Companies.

CIN Status
L02423MP1993PLC007840 Current
U02423MP1993PLC007840 Previous

Associated Brands with Beryl Drugs Limited

Beryl Drugs Limited operates one associated brand: Beryl Drugs. These brands represent Beryl Drugs Limited's diversified market presence and brand portfolio.

Brand Description Website
Beryl Drugs
Pharmaceutical and allied healthcare products are manufactured for various supplies. beryldrugs.com

Business Activity of Beryl Drugs Limited

Beryl Drugs Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products Locked
Premium access

Business activity turnover details for Beryl Drugs Limited

Turnover contribution percentages and historical activity changes require an active report plan.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Verified entity values are shown only after access is granted.

Auditor Details of Beryl Drugs Limited

Beryl Drugs Limited is audited by Subhash Chand Jain Anurag & Associates (ICAI peer reviewed, certificate valid till 2027-03-31) for the financial year 2026, as reported in its BSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.

Name Financial year Audit opinion
Subhash Chand Jain Anurag & Associates (ICAI peer reviewed, certificate valid till 2027-03-31) FY 2026 Declaration of unmodified opinion

Board of Directors of Beryl Drugs Limited

Beryl Drugs Limited is currently managed by 6 directors, with 14 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Sudhir Sethi Director 12 Dec 2000 25 Years 7 Months Current
Abhinav Naik
Also directs: Beryl Securities Limited
Director 30 May 2019 7 Years 1 Months Current
Shreya Saraf
Also directs: Narmada Extrusions Limited, Boyd Thermal Systems India Private Limited
Director 30 May 2019 7 Years 1 Months Current
Sanjay Sethi Managing Director 12 Dec 2000 25 Years 7 Months Current
Shailendra Pathak
Also directs: Aminova Infusions Private Limited
Additional Director 03 Jan 2026 0 Years 6 Months Current
Neha Sarda
Also directs: Beryl Securities Limited, Recharge Trendd Setter Limited
Additional Director 03 Jan 2026 0 Years 6 Months Current
View all directors

Financials of Beryl Drugs Limited FY 2026 filings available

Beryl Drugs Limited reported revenue of ₹18.82 Cr (down 11% YoY) for FY 2026.

Revenue · FY 2026
₹18.82 Cr ▼ 11%
Profit · FY 2026
₹42.48 Lakh ▼ 26.62%
Computed EBITDA · FY 2026
₹2.43 Cr ▼ 8.16%
Revenue₹ Cr · Standalone0102030FY 2019: ₹13 Cr13FY 2019FY 2020: ₹13 Cr · -1.1% YoY12.8-1.1%FY 2020FY 2021: ₹14 Cr · +10% YoY14.1+10%FY 2021FY 2022: ₹15 Cr · +3.6% YoY14.6+3.6%FY 2022FY 2023: ₹27 Cr · +84.1% YoY26.9+84.1%FY 2023FY 2024: ₹27 Cr · -0.6% YoY26.7-0.6%FY 2024FY 2025: ₹21 Cr · -20.9% YoY21.1-20.9%FY 2025FY 2026: ₹19 Cr · -11% YoY18.8-11%FY 2026
Net Profit₹ Cr · Standalone-1-0.500.51FY 2019: ₹1 Cr0.6FY 2019FY 2020: ₹0 Cr · -91.9% YoY0-91.9%FY 2020FY 2021: ₹0 Cr · +400.2% YoY0.2+400.2%FY 2021FY 2022: ₹1 Cr (loss) · -375% YoY-0.7FY 2022FY 2023: ₹1 Cr · +216.3% YoY0.8+216.3%FY 2023FY 2024: ₹1 Cr · +0.3% YoY0.8+0.3%FY 2024FY 2025: ₹1 Cr · -24.7% YoY0.6-24.7%FY 2025FY 2026: ₹0 Cr · -26.6% YoY0.4-26.6%FY 2026
Quarterly Revenue₹ Cr · vs same quarter last year02.557.5Q1'25: ₹6 Cr6.2Q1'25Q2'25: ₹6 Cr5.6Q2'25Q3'25: ₹5 Cr5.3Q3'25Q4'25: ₹4 Cr4Q4'25Q1'26: ₹5 Cr · -23.3% YoY4.8-23.3%Q1'26Q2'26: ₹5 Cr · -8.8% YoY5.1-8.8%Q2'26Q3'26: ₹4 Cr · -28.9% YoY3.8-28.9%Q3'26Q4'26: ₹5 Cr · +29.1% YoY5.1+29.1%Q4'26
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Revenue from Operations ₹18.82 Cr ₹21.15 Cr ₹26.73 Cr ₹26.89 Cr ₹14.6 Cr ₹14.09 Cr ₹12.82 Cr ₹12.96 Cr
Other Income ₹49 Lakh ₹1.41 Cr ₹39.51 Lakh ₹26.87 Lakh ₹16.49 Lakh ₹18.71 Lakh ₹23.31 Lakh ₹24.38 Lakh
Total Income ₹19.31 Cr ₹22.55 Cr ₹27.12 Cr ₹27.16 Cr ₹14.77 Cr ₹14.28 Cr ₹13.05 Cr ₹13.2 Cr
Cost of Materials Consumed ₹10.51 Cr ₹11.12 Cr ₹13.31 Cr ₹14.23 Cr ₹8.71 Cr ₹7.45 Cr ₹6.68 Cr ₹6.85 Cr
Purchases of Stock-in-Trade ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Changes in Inventories -₹74.32 Lakh -₹33.7 Lakh -₹16.72 Lakh ₹31.25 Lakh -₹30.41 Lakh -₹3.27 Lakh -₹7 Lakh ₹12.95 Lakh
Employee Benefit Expense ₹2.53 Cr ₹2.21 Cr ₹1.93 Cr ₹1.7 Cr ₹1.31 Cr ₹1.18 Cr ₹96.53 Lakh ₹84.55 Lakh
Finance Costs ₹34.43 Lakh ₹52.97 Lakh ₹46.35 Lakh ₹41.56 Lakh ₹43.68 Lakh ₹46.57 Lakh ₹32.1 Lakh ₹14.61 Lakh
Depreciation & Amortisation ₹1.49 Cr ₹1.25 Cr ₹1.2 Cr ₹81.44 Lakh ₹1.09 Cr ₹1.27 Cr ₹65.94 Lakh ₹32.41 Lakh
Other Expenses ₹4.59 Cr ₹6.92 Cr ₹9.38 Cr ₹8.71 Cr ₹4.48 Cr ₹4.05 Cr ₹4.34 Cr ₹4.11 Cr
Total Expenses ₹18.72 Cr ₹21.69 Cr ₹26.12 Cr ₹26.17 Cr ₹15.72 Cr ₹14.38 Cr ₹12.89 Cr ₹12.41 Cr
Profit Before Exceptional Items & Tax ₹58.8 Lakh ₹86.57 Lakh ₹1.01 Cr ₹98.39 Lakh -₹95.03 Lakh -₹10.39 Lakh ₹15.79 Lakh ₹79.63 Lakh
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 ₹45.18 Lakh ₹0 ₹0
Profit Before Tax ₹58.8 Lakh ₹86.57 Lakh ₹1.01 Cr ₹98.39 Lakh -₹95.03 Lakh ₹34.79 Lakh ₹15.79 Lakh ₹79.63 Lakh
Total Tax Expense ₹16.32 Lakh ₹28.68 Lakh ₹24.11 Lakh ₹21.78 Lakh -₹29.13 Lakh ₹10.83 Lakh ₹11 Lakh ₹20.56 Lakh
Net Profit ₹42.48 Lakh ₹57.89 Lakh ₹76.86 Lakh ₹76.61 Lakh -₹65.9 Lakh ₹23.96 Lakh ₹4.79 Lakh ₹59.07 Lakh
Other Comprehensive Income -₹1.81 Lakh ₹16,000 ₹8.83 Lakh ₹67,000 ₹2.32 Lakh ₹6.43 Lakh ₹4.94 Lakh ₹27.03 Lakh
Total Comprehensive Income ₹40.67 Lakh ₹58.05 Lakh ₹85.69 Lakh ₹77.28 Lakh -₹63.58 Lakh ₹30.39 Lakh ₹9.73 Lakh ₹86.1 Lakh
EBITDA (computed) ₹2.43 Cr ₹2.64 Cr ₹2.67 Cr ₹2.21 Cr ₹57.3 Lakh ₹1.64 Cr ₹1.14 Cr ₹1.27 Cr
Basic EPS ₹0.30 ₹1.14 ₹1.52 ₹1.52 ₹-1.30 ₹0.47 ₹0.09 ₹1.16
Diluted EPS ₹0.30 ₹1.14 ₹1.52 ₹1.52 ₹-1.30 ₹0.47 ₹0.09 ₹1.16
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Total Assets ₹14.96 Cr ₹15.96 Cr ₹17.49 Cr ₹17.51 Cr ₹17.82 Cr ₹18.65 Cr ₹16.91 Cr ₹14.57 Cr
Non-current Assets ₹7.94 Cr ₹6.92 Cr ₹7.27 Cr ₹7.2 Cr ₹7.2 Cr ₹8.5 Cr ₹9.4 Cr ₹8.68 Cr
Current Assets ₹7.03 Cr ₹9.04 Cr ₹10.22 Cr ₹10.32 Cr ₹10.58 Cr ₹10.11 Cr ₹7.51 Cr ₹5.89 Cr
Property, Plant & Equipment ₹6.82 Cr ₹6 Cr ₹5.96 Cr ₹5.81 Cr ₹5.86 Cr ₹7.32 Cr ₹8.47 Cr ₹1.81 Cr
Inventories ₹3.13 Cr ₹1.9 Cr ₹1.26 Cr ₹1.05 Cr ₹2.98 Cr ₹2.27 Cr ₹1.16 Cr ₹76.38 Lakh
Trade Receivables ₹2.09 Cr ₹5.46 Cr ₹7.58 Cr ₹6.9 Cr ₹4.45 Cr ₹4.54 Cr ₹3.45 Cr ₹3.44 Cr
Cash & Equivalents ₹27.35 Lakh ₹81.44 Lakh ₹12.49 Lakh ₹28.31 Lakh ₹27.14 Lakh ₹45.21 Lakh ₹39.63 Lakh ₹9.98 Lakh
Equity (Net Worth) ₹9.89 Cr ₹9.5 Cr ₹8.92 Cr ₹8.07 Cr ₹7.29 Cr ₹7.93 Cr ₹7.63 Cr ₹7.53 Cr
Equity Share Capital ₹5.09 Cr ₹5.09 Cr ₹5.09 Cr ₹5.09 Cr ₹5.09 Cr ₹5.09 Cr ₹5.09 Cr ₹5.09 Cr
Borrowings (Non-current) ₹0 ₹1.74 Cr ₹2.4 Cr ₹2.72 Cr ₹1.68 Cr ₹1.99 Cr ₹26.57 Lakh ₹21.07 Lakh
Borrowings (Current) ₹2.39 Cr ₹2.34 Cr ₹2.69 Cr ₹1.82 Cr ₹3.62 Cr ₹2.35 Cr ₹2.39 Cr ₹1.76 Cr
Total Debt (computed) ₹2.39 Cr ₹4.07 Cr ₹5.09 Cr ₹4.54 Cr ₹5.29 Cr ₹4.34 Cr ₹2.66 Cr ₹1.97 Cr
Current Liabilities ₹4.53 Cr ₹4.3 Cr ₹5.76 Cr ₹6.33 Cr ₹7.29 Cr ₹8.21 Cr ₹6.63 Cr ₹5.53 Cr
Total Liabilities ₹5.08 Cr ₹6.46 Cr ₹8.56 Cr ₹9.45 Cr ₹10.53 Cr ₹10.72 Cr ₹9.29 Cr ₹7.04 Cr
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹3.65 Cr ₹2.64 Cr ₹1.01 Cr ₹2.48 Cr -₹28.67 Lakh
Investing Cash Flow -₹2.16 Cr -₹39.7 Lakh -₹1.26 Cr -₹1.3 Cr ₹53.79 Lakh
Financing Cash Flow -₹2.03 Cr -₹1.55 Cr ₹8.83 Lakh -₹1.17 Cr -₹43.19 Lakh
Capital Expenditure ₹3.82 Cr ₹2.19 Cr ₹1.35 Cr ₹1.56 Cr ₹41.55 Lakh
Free Cash Flow (computed) -₹17.47 Lakh ₹45.16 Lakh -₹33.88 Lakh ₹91.7 Lakh -₹70.22 Lakh
Dividends Paid ₹0 ₹0 ₹0 ₹0 ₹0
Net Change in Cash -₹54.08 Lakh ₹68.96 Lakh -₹15.82 Lakh ₹1.18 Lakh -₹18.07 Lakh
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25
Revenue from Operations ₹5.13 Cr ₹3.78 Cr ₹5.12 Cr ₹4.79 Cr ₹3.97 Cr ₹5.31 Cr ₹5.61 Cr ₹6.25 Cr
Other Income ₹33.83 Lakh ₹7.36 Lakh ₹3.66 Lakh ₹4.15 Lakh ₹1.25 Cr ₹9.34 Lakh ₹3.1 Lakh ₹3.82 Lakh
Total Income ₹5.47 Cr ₹3.85 Cr ₹5.16 Cr ₹4.84 Cr ₹5.22 Cr ₹5.4 Cr ₹5.65 Cr ₹6.29 Cr
Cost of Materials Consumed ₹3.43 Cr ₹2.08 Cr ₹2.79 Cr ₹2.21 Cr ₹2.46 Cr ₹2.63 Cr ₹2.67 Cr ₹3.36 Cr
Purchases of Stock-in-Trade ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Changes in Inventories -₹30.69 Lakh -₹4.53 Lakh -₹20.76 Lakh -₹18.34 Lakh ₹35.25 Lakh -₹79.41 Lakh ₹1.35 Lakh ₹9.11 Lakh
Employee Benefit Expense ₹62.9 Lakh ₹78.91 Lakh ₹57.68 Lakh ₹53.39 Lakh ₹59.44 Lakh ₹62.01 Lakh ₹50.13 Lakh ₹49.64 Lakh
Finance Costs ₹7.15 Lakh ₹9.17 Lakh ₹8.02 Lakh ₹10.09 Lakh ₹7.9 Lakh ₹12.04 Lakh ₹12.26 Lakh ₹20.77 Lakh
Depreciation & Amortisation ₹40.26 Lakh ₹31.83 Lakh ₹39.15 Lakh ₹38.08 Lakh ₹31.65 Lakh ₹31.26 Lakh ₹33.48 Lakh ₹28.17 Lakh
Other Expenses ₹37.51 Lakh ₹1.22 Cr ₹1.27 Cr ₹1.73 Cr ₹1.31 Cr ₹2.36 Cr ₹1.9 Cr ₹1.35 Cr
Total Expenses ₹4.6 Cr ₹4.46 Cr ₹4.9 Cr ₹4.77 Cr ₹5.12 Cr ₹5.24 Cr ₹5.54 Cr ₹5.79 Cr
Profit Before Exceptional Items & Tax ₹86.58 Lakh -₹60.78 Lakh ₹26.03 Lakh ₹6.97 Lakh ₹10.18 Lakh ₹16.05 Lakh ₹10.77 Lakh ₹49.57 Lakh
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹86.58 Lakh -₹60.78 Lakh ₹26.03 Lakh ₹6.97 Lakh ₹10.18 Lakh ₹16.05 Lakh ₹10.77 Lakh ₹49.57 Lakh
Total Tax Expense ₹30.33 Lakh -₹44.01 Lakh ₹25.14 Lakh ₹4.86 Lakh -₹5.01 Lakh ₹10.83 Lakh ₹10.08 Lakh ₹12.78 Lakh
Net Profit ₹56.25 Lakh -₹16.77 Lakh ₹89,000 ₹2.11 Lakh ₹15.19 Lakh ₹5.22 Lakh ₹69,000 ₹36.79 Lakh
Other Comprehensive Income -₹2.11 Lakh ₹6.83 Lakh -₹24,000 ₹24,000 -₹62,000 ₹26,000 ₹25,000 ₹27,000
Total Comprehensive Income ₹54.14 Lakh -₹9.94 Lakh ₹65,000 ₹2.35 Lakh ₹14.57 Lakh ₹5.48 Lakh ₹94,000 ₹37.06 Lakh
EBITDA (computed) ₹1.34 Cr -₹19.78 Lakh ₹73.2 Lakh ₹55.14 Lakh ₹49.73 Lakh ₹59.35 Lakh ₹56.51 Lakh ₹98.51 Lakh
Basic EPS ₹1.11 ₹-0.33 ₹0.02 ₹0.04 ₹0.30 ₹0.10 ₹0.01 ₹0.73
Diluted EPS ₹1.11 ₹-0.33 ₹0.02 ₹0.04 ₹0.30 ₹0.10 ₹0.01 ₹0.73
Latest 8 quarters shown.
Want more history and ratios?
You're viewing the latest exchange-filed financials for Beryl Drugs Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Charges & Borrowings of Beryl Drugs Limited

Open charges
₹2.85 Cr
Satisfied charges
₹9.99 Cr
Breakdown by lending institutions
Others₹2.85 Cr
Latest charge details
DateLenderAmountStatus
18 Mar 1997 Others ₹2.85 Cr Open
27 Jun 2024 Others ₹1.75 Cr Satisfied
16 May 2024 Others ₹45 Lakh Satisfied
20 Mar 2023 Others ₹1.15 Cr Satisfied
12 Jun 2020 Others ₹45 Lakh Satisfied

Total charge records: 12 View all charges

Employees and EPFO Compliance at Beryl Drugs Limited

View historical data on people associated with Beryl Drugs Limited, including employment history and EPFO contributions.

Premium access

Employee and EPFO history for Beryl Drugs Limited

Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

GST Compliance of Beryl Drugs Limited

Premium access

GST registrations and filing compliance for Beryl Drugs Limited

State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

Credit Ratings, Litigation & Regulatory Alerts for Beryl Drugs Limited

Premium access

Credit ratings, litigation, and regulatory alerts for Beryl Drugs Limited

Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

MSME Payment Delays by Beryl Drugs Limited

Premium access

MSME payment history for Beryl Drugs Limited

Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.

  • Outstanding amounts
  • Delay periods and reasons
  • MSME-1 filing history
  • Vendor payment signals

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Beryl Drugs Limited

Premium access

Corporate group structure for Beryl Drugs Limited

Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Beryl Drugs Limited

Premium access

MCA filings and documents for Beryl Drugs Limited

Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Recent Activity on Beryl Drugs Limited

Charges
11 May 2026
A charge registered on 20 Mar 2023 via Charge ID 100693923 with Others was fully satisfied on 11 May 2026.
Charges
30 Apr 2026
A charge registered on 27 Jun 2024 via Charge ID 100945463 with Others was fully satisfied on 30 Apr 2026.
Directors
24 Jan 2026
Kamlesh Gupta was appointed as a Company Secretary on 24 Jan 2026 & has been associated with this company since 5 months 27 days.
Directors
03 Jan 2026
Shailendra Pathak was appointed as a Additional Director on 03 Jan 2026 & has been associated with this company since 6 months 18 days.
Directors
03 Jan 2026
Neha Sarda was appointed as a Additional Director on 03 Jan 2026 & has been associated with this company since 6 months 18 days.
Activity
30 Sep 2025
Beryl Drugs Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.

Frequently Asked Questions about Beryl Drugs Limited

Beryl Drugs Limited is an active public limited company in the pharma sector based in Indore, Madhya Pradesh, India. It was incorporated on 24 August 1993 (33+ years old) and is registered under CIN L02423MP1993PLC007840. Listed on BSE: 524606. The company has 22 employees.

Beryl Drugs Limited reported revenue of ₹18.82 Cr for FY 2026 (down 11% YoY) based on standalone BSE filings.

The current directors of Beryl Drugs Limited are:

The primary industry of Beryl Drugs Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.

Yes. Beryl Drugs Limited is listed on BSE with code 524606.

Beryl Drugs Limited can be reached at the registered office: 29 Neer Nagar Mayank Water Park Road Bicholi, Indore, Madhya Pradesh, India – 452016, or through the website beryldrugs.com.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - sourced from MCA, SEBI and RBI filings.

Subscription plans available